Pricing
  1. JP-listed companies
  2. PhoenixBio Co.,Ltd.
  3. Financials
  4. Net income margin (%)

PhoenixBio Co.,Ltd.【JP:6190】

Market cap
¥1.8B
P/E ratio
16.8x
Phoenix Bio provides pharmaceutical testing services using PXB mice with human liver cells to help drug companies predict how medicines work in people.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndNet income margin (%) YoY (%)
Mar 31, 2025-29.1-1993.97%
Mar 31, 20241.5-93.38%
Mar 31, 202323.2-179.31%
Mar 31, 2022-29.3+24.71%
Mar 31, 2021-23.5-25.95%
Mar 31, 2020-31.7+30.94%
Mar 31, 2019-24.2-19.29%
Mar 31, 2018-30-387.36%
Mar 31, 201710.4+1.47%
Mar 31, 201610.3+59.78%
Mar 31, 20156.4-48.42%
Mar 31, 201412.5-296.07%
Mar 31, 2013-6.4-78.97%
Mar 31, 2012-30.3

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)